Latest Deals
Pfizer will pay $150m upfront with more than $1.9bn available for YaoPharma, Credit: ShU studio/Shutterstock.com
Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA
Pfizer has forged a licencing deal worth up to $2bn with YaoPharma. Pfizer has paid $150m for the exclusive licence to further develop, manufacture and commercialise YaoPharma’s obesity asset, YP05002, worldwide. YaoPharma will gain up to $1.94bn if certain development, regulatory and commercial milestones are met, as well as tiered royalties on sales if the drug is approved.
Novartis and UK-based Relation forge R&D deal worth up to $1.7bn
Novartis has teamed up with AI-led biotech Relation Therapeutics in a deal worth up to approximately $1.7bn to discover and develop novel targets for atopic diseases. Through the agreement, the Swiss big pharma company will hand over $55m in upfront, equity investment and R&D funding payments for the global development and commercialisation rights to any resulting targets created through this partnership.
Mirum to buy Bluejay for up to $820m in rare liver disease push
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver disease candidate to its portfolio. According to the agreement, US-based Mirum will pay $250m in cash and $370m in its own stock upfront to buy the private biotech. Bluejay is also in line to receive a further $200m in potential sales-based milestones.
Viatris signs agreements with Biocon on $815m stake sale
Viatris has signed definitive agreements for the sale of its equity stake in Biocon Biologics to Biocon for $815m. Viatris will sell all of its convertible preferred equity in Biocon Biologics. The deal value comprises $415m in newly issued Biocon equity shares and $400m in cash.
